Silverfin false false 31/03/2025 01/04/2024 31/03/2025 Mrs I Frisby 25/03/2022 25 June 2025 The principal activity of the company during the financial year was the provision of pharmaceutical consultancy services. NI686898 2025-03-31 NI686898 bus:Director1 2025-03-31 NI686898 core:CurrentFinancialInstruments 2025-03-31 NI686898 core:CurrentFinancialInstruments 2024-03-31 NI686898 2024-03-31 NI686898 core:ShareCapital 2025-03-31 NI686898 core:ShareCapital 2024-03-31 NI686898 core:RetainedEarningsAccumulatedLosses 2025-03-31 NI686898 core:RetainedEarningsAccumulatedLosses 2024-03-31 NI686898 bus:OrdinaryShareClass1 2025-03-31 NI686898 2024-04-01 2025-03-31 NI686898 bus:FilletedAccounts 2024-04-01 2025-03-31 NI686898 bus:SmallEntities 2024-04-01 2025-03-31 NI686898 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 NI686898 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 NI686898 bus:Director1 2024-04-01 2025-03-31 NI686898 2023-04-01 2024-03-31 NI686898 core:CurrentFinancialInstruments 2024-04-01 2025-03-31 NI686898 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 NI686898 bus:OrdinaryShareClass1 2023-04-01 2024-03-31 NI686898 1 2024-04-01 2025-03-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: NI686898 (Northern Ireland)

FQS PHARMA UK LIMITED

Unaudited Financial Statements
For the financial year ended 31 March 2025
Pages for filing with the registrar

FQS PHARMA UK LIMITED

Unaudited Financial Statements

For the financial year ended 31 March 2025

Contents

FQS PHARMA UK LIMITED

BALANCE SHEET

As at 31 March 2025
FQS PHARMA UK LIMITED

BALANCE SHEET (continued)

As at 31 March 2025
Note 2025 2024
£ £
Current assets
Debtors 3 15,326 0
Cash at bank and in hand 13,009 43,411
28,335 43,411
Creditors: amounts falling due within one year 4 ( 5,378) ( 8,999)
Net current assets 22,957 34,412
Total assets less current liabilities 22,957 34,412
Net assets 22,957 34,412
Capital and reserves
Called-up share capital 5 2 2
Profit and loss account 22,955 34,410
Total shareholder's funds 22,957 34,412

For the financial year ending 31 March 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of FQS Pharma UK Limited (registered number: NI686898) were approved and authorised for issue by the Director on 25 June 2025. They were signed on its behalf by:

Mrs I Frisby
Director
FQS PHARMA UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2025
FQS PHARMA UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

FQS Pharma UK Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in Northern Ireland. The address of the Company's registered office and principal place of business is The Mount Business Centre, 2 Woodstock Link, Belfast, BT6 8DD, Northern Ireland, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the Balance Sheet date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Balance Sheet date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on tax rates and laws substantively enacted at the balance sheet date. Deferred tax assets and liabilities are not discounted.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

2025 2024
Number Number
Monthly average number of persons employed by the Company during the year, including the director 1 1

3. Debtors

2025 2024
£ £
Trade debtors 11,890 0
Prepayments 779 0
Corporation tax 2,657 0
15,326 0

4. Creditors: amounts falling due within one year

2025 2024
£ £
Trade creditors 49 0
Amounts owed to director 1,093 780
Accruals 2,200 0
Taxation and social security 1,849 5,732
Other creditors 187 2,487
5,378 8,999

There are no amounts included above in respect of which any security has been given by the small entity.

5. Called-up share capital

2025 2024
£ £
Allotted, called-up and fully-paid
2 Ordinary shares of £ 1.00 each 2 2

6. Ultimate controlling party

Parent Company:

FQS Industries Limited
Main Street,
Mullinavat
Kilkenny
Ireland

The company, FQS Pharma UK Limited, is owned entirely by its parent company based in Ireland, FQS Industries Limited. This company is jointly owned by Ms Irene and Mr George Frisby.